Assoc Prof Yoland Antill, Chair of ANZGOG’s Uterine Tumour Type Working Group, shares updates from the group’s recent meeting on protocol developments in existing research studies and upcoming trials for endometrial cancer patients.
Assoc Prof Yoland Antill
Assoc Prof Yoland Antill, Medical Oncologist, is the chair of ANZGOG’s Uterine Tumour Type Working Group, and a member of the Research Advisory Committee.
The members of the Uterine Tumour Working Group met again in an online forum- will the COVID restrictions ever allow us to meet in person again?
The meeting was well attended by most members with the addition of invited ANZGOG member Ganessan Kichendasse, a medical oncologist from Adelaide’s Flinders Cancer Centre. We welcomed new consumer member Kathryn Cornwaite who joins ongoing consumer members, Lesley McQuire and Wanda Lawson. Kathryn joins this group having worked with ANZGOG’s Cervical Cancer Working Group in previous years.
The group learned of updates in the protocol development of a number of research studies- including EPOCH (Advanced Uterine Carcinosarcomas), ADELE (Adjuvant treatment for Endometrial Cancer), Her2 Study (Her2 positive endometrial cancers and carcinosarcomas) and ENDO3 (Surgical study in endometrial cancer) and welcomed the news that AtTEND (chemotherapy and immunotherapy in advanced endometrial cancers) is now open for recruitment at a number of sites around Australia.
Additional discussion was held around the preclinical work (preliminary laboratory work needed prior to a clinical trial) in a number of laboratories. The results of this exciting work are eagerly awaited to determine how best to move forward with trial design in the future.
“AtTEND (chemotherapy and immunotherapy in advanced endometrial cancers) is now open for recruitment at a number of sites around Australia.“
Dr Kichendasse presented a new trial proposal to the group for the treatment of the rare carcinosarcoma and is now working with a collaborative group to continue evolving the trial design.
Finally, with the recognition of differences in clinical outcomes of endometrial cancers with POLE-hypermutation, the group devoted some time exploring the way testing for this tumour type might take place.
All in all, another busy meeting with lots of ideas shared and motivation boosted to continue working towards better outcomes for women with uterine cancers.
Since our beginning in 2000, ANZGOG has conducted 37 clinical trial studies, with close to 4000 patients participating in these trials. ANZGOG currently has 13 open trials. To find out more, please visit our trials page.
